Kanneboyina Nagaraju
pharmaceutical sciences researcher
Kanneboyina Nagaraju is a medical scientist and immunologist who is credited with creating the MHC Class I transgenic mouse model for autoimmune myositis. Nagaraju is also credited with identifying novel glucocorticoid analogs with reduced side effect profiles in collaboration with Eric Hoffman and John McCall. He led international efforts to improve rigor and reproducibility of preclinical drug trials and phenotyping in neuromuscular disease models.
After receiving veterinary training at the Sri Venkateswara Veterinary University and the Indian Veterinary Research Institute, he attended the Sanjay Gandhi Postgraduate Institute of Medical Sciences where he received his PhD in Immunology and completed his post-doctoral training at NIH. Nagaraju was a tenure-track faculty member at the Johns Hopkins University School of Medicine and a tenured professor at Children's National Medical Center and George Washington University School of Medicine. He is a Professor, served as Founding Chair of the Department of Pharmaceutical Sciences, and currently serves as Dean at the School of Pharmacy and Pharmaceutical Sciences, SUNY-Binghamton University. He is Co-Founder of AGADA Biosciences and ReveraGen BioPharma.
The public source identifies “Kanneboyina Nagaraju” as pharmaceutical sciences researcher. This brief keeps that definition visible, then builds a research path around Kanneboyina, Nagaraju and pharmaceutical.
Why this record matters
A short description can identify a subject without explaining its stakes. For “Kanneboyina Nagaraju”, the useful work is to connect “pharmaceutical sciences researcher” to the records capable of establishing context and consequence.
Biographical claims are most persuasive when dates, appointments and relationships can be traced to records created close to the events described. The source revision retrieved here is dated Jun 5, 2026. The linked authority identifier is Q27662260. None of the 0 selected statements returned an explicit reference.
Later biographies can compress uncertainty and repeat inherited reputations, so apparently settled claims may still require comparison. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Read biographical claims against dates, named institutions and the cited references. Distinguish a subject’s later reputation from evidence produced during their lifetime.
- Establishing names and roles
- Building a first chronology
- Locating cited institutions
Personal papers, civil or court records, institutional files and the scholarship cited by the source.
Three-step research path
- Establish the record: confirm the title “Kanneboyina Nagaraju”, its source revision and the description used here.
- Expand the search: follow Kanneboyina Nagaraju primary sources, Kanneboyina Nagaraju archive and Kanneboyina research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “Kanneboyina Nagaraju”?
- How has the subject’s reputation changed across later accounts?
- Which claims depend on a single source or contested interpretation?
Search terms from this dossier
This entry incorporates text from “Kanneboyina Nagaraju” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.